

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199528244 B2**
(10) Patent No. **704286**

(54) Title
Stable vitamin A

(51)⁶ International Patent Classification(s)
C07C 403/08 C07C 403/12

(21) Application No: 199528244 (22) Application Date: 1995 .06 .09

(87) WIPO No: W096/04243

(30) Priority Data

(31) Number	(32) Date	(33) Country
08/285242	1994 .08 .03	US
08/438869	1995 .05 .23	US

(43) Publication Date : 1996 .03 .04
(43) Publication Journal Date : 1996 .04 .18
(44) Accepted Journal Date : 1999 .04 .15

(71) Applicant(s)
The Procter and Gamble Company

(72) Inventor(s)
Robert Joseph Sarama; Thomas Joseph Wehmeier; Michael Robert Sevenants;
Robert Alan Sanders

(74) Agent/Attorney
PHILLIPS ORMONDE and FITZPATRICK, 367 Collins Street, MELBOURNE VIC 3000

(56) Related Art
FR 1425252

OPI DATE 04/03/96 APPLN. ID 28244/95
AOJP DATE 18/04/96 PCT NUMBER PCT/US95/07419



AU9528244

I.

(51) International Patent Classification ⁶ : C07C 403/08, 403/12		A1	(11) International Publication Number: WO 96/04243
			(43) International Publication Date: 15 February 1996 (15.02.96)
(21) International Application Number: PCT/US95/07419		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 9 June 1995 (09.06.95)			
(30) Priority Data: 08/285,242 3 August 1994 (03.08.94) US 08/438,869 23 May 1995 (23.05.95) US			
(71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).			
(72) Inventors: SARAMA, Robert, Joseph; 136 Shingle Oak Drive, Loveland, OH 45140 (US). WEHMEIER, Thomas, Joseph; 960 Hickoryview Drive, Cincinnati, OH 45233 (US). SEVENANTS, Michael, Robert; 324 Overton Street, Newport, KY 41071 (US). SANDERS, Robert, Alan; 915 Maple Ridge Court, Fairfield, OH 45014 (US).			
(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).		Published <i>With international search report.</i>	
(54) Title: STABLE VITAMIN A			
(57) Abstract A process for purifying vitamin A consisting of heating a vitamin A preparation in an inert atmosphere, at a temperature below 170 °C and a pressure of less than 4 mm of mercury, said heating taking place in a vessel shielded from light is disclosed. The vitamin A obtained from this process is mixed with from 0.5:1 to 2:1 parts of tocopherol to vitamin A. The vitamin A and tocopherol mixture can be encapsulated in acacia gum, starch, pectins or other suitable materials. When the vitamin A is encapsulated, the level of tocopherol required is less, preferably from 0.05:1 to about 1:1 parts of tocopherol to vitamin A is used in an encapsulated vitamin A composition. Other antioxidants can be added.			

STABLE VITAMIN A

TECHNICAL FIELD

The field of this invention is a purified and stabilized vitamin A or vitamin A derivative which is substantially free of off flavor and is odorless.

BACKGROUND OF THE INVENTION

Vitamin A is commercially prepared by extraction from fish liver oils or by chemical synthesis from the reaction of beta ionone and a propargyl halide. Other syntheses include starting with beta ionone, converting it to beta iononyl, and reacting it with 3-formylcrotonyl acetate to make retinol acetate. Alternatively, beta ionone can be converted to the corresponding aldehyde and through a Grignard reaction with 3 methyl-2-pentene-4-yn-1-ol and a partial hydrogenation and rearrangement converts it to retinol acetate. Retinol acetate is converted to retinol palmitate through a transesterification reaction with methyl palmitate. Both retinol acetate and retinol palmitate are commonly used for supplementation.

The most stable and more bioavailable form of Vitamin A is the trans isomer. The cis isomeric forms, i.e., 13-cis retinol, 9-cis retinol, and 9, 13-di-cis retinol materials are less stable. Cis isomers are formed during production and they oxidize more readily than the trans isomers.

Commercial vitamin A contains a number of impurities which are present either due to oxidation or as left over solvents or by products of the synthesis of vitamin A. One of the key reactants and/or oxidation products of vitamin A is beta ionone. The percentage of beta ionone as well as the level of cis isomers of vitamin A can be used to determine vitamin A quality.

Even when vitamin A palmitate or acetate is prepared and purified, it readily oxidizes creating beta-ionone and other oxidation products. Spray dried vitamin A, that is, vitamin A which is spray dried or partially encapsulated with pectin, starches, gum, or other suitable material, is more stable to oxidation, but it also can contain from 10-30% cis isomers vitamin A and solvents remaining from the synthesis or the transesterification reaction. Even this form of vitamin A can oxidize over time.

Beta ionone which is a key impurity in vitamin A has a cedar wood or raspberry aroma and is used in perfumes. It has a very low threshold level. This is just one of many odors associated with vitamin A oxidation products. Aldehydes and ketones are also formed, particularly hexanal, 5-nonen-2-one, 2-decenal, and octanal. Hydrocarbons such as hexane, cyclopentane, ethyl cyclohexane and nonane can also be present. All of these materials have unpleasant odors and flavors.

Accordingly, it is desirable to have a vitamin A which is substantially free of oxidation products, solvents, and has less than 5% of the cis-isomer. Such a
 5 vitamin A has been found to be tasteless and odorless. It would also be desirable to stabilize this material against oxidation.

It has now been found that vitamin A can be purified to remove essentially all of the volatile materials boiling below 50°C, and, stabilized to prevent further oxidation. It would therefore be desirable to provide a tasteless, odorless,
 10 storage-stable vitamin A. It would further be desirable to make a vitamin A which contains β -ionone at levels below its threshold value.

The advantages provided by the present invention will be evident from the description following.

SUMMARY OF THE INVENTION

15 The present invention provides a shelf stable, purified vitamin A preparation wherein said preparation is substantially free of beta-ionone and solvents, and wherein less than 5% of the vitamin A is a cis-isomer, comprising a mixture of tocopherol and vitamin A, the ratio of tocopherol to vitamin A being from 0.5:1 to 2:1.

20 The present invention further provides a shelf stable, purified vitamin A preparation which is substantially free of beta-ionone and solvents, and wherein less than 5% of the vitamin A is a cis-isomer, comprising a mixture of tocopherol and vitamin A, the ratio of tocopherol to vitamin A being from 0.05:1 to 2:1; said vitamin A being encapsulated.

25 A process for purifying vitamin A consisting of heating a vitamin A preparation in an inert atmosphere, at a temperature below 170°C and pressure of less than 4mm of mercury, said heating taking place in a vessel shielded from light is disclosed. The vitamin A obtained from this process is mixed with from 0.5:1 to 2:1 parts of tocopherol to vitamin A. The vitamin A and tocopherol
 30 mixture can be encapsulated in acacia gum, starch, pectins, lipid hardstocks, ethyl cellulose or other suitable materials. Other antioxidants can be added.



2a

When the vitamin A is encapsulated or solidified, the tocopherol to vitamin A level is from about 0.05:1 to about 2:1. Preferably the ratio is from 0.1:1 to 1:1.

In its process aspect, the present invention provides a process for removing off-flavour and odors from vitamin A comprising:

(a) degassing a sample of vitamin A;

(b) heating degassed vitamin A in the absence of light at a pressure of less than 4 mm Hg and a temperature of less than 170°C with an inert gas sparge until substantially all of the beta-ionone and solvents are removed;

(c) mixing the vitamin A with from 0.5 to 2 part of tocopherol/part of vitamin A.

In another of its process aspects, the present invention provides a process for removing off-flavor and odors from vitamin A comprising:

(a) degassing a sample of vitamin A;

(b) heating degassed vitamin A in the absence of light at a pressure of less than 4 mm Hg and a temperature of less than 170°C with an inert gas sparge until substantially all of the beta-ionone and solvents are removed;

(c) mixing the vitamin A with from 0.05:1 to 2:1 parts of tocopherol/part of vitamin A; and

(d) encapsulating the vitamin A tocopherol mixture with a member of the group selected from gums, starches, pectin, gelatin, lipid hardstocks, ethyl cellulose or mixtures thereof.

DETAILED DESCRIPTION OF THE INVENTION

All percentages used herein are by weight unless otherwise indicated.

As used herein, the term "comprising" encompasses the more narrow terms "consisting essentially of" and "consisting of".

Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives or components or integers or steps.



C:\WINVORD\ILONA\W\H\ML\HSPEC\15P28244.DOC

2b

As used herein, the term "Vitamin A" includes retinol and the alkyl esters of vitamin A. The alkyl ester group can have from 2 to 22 carbon atoms and can be
5 saturated, branched or straight chain. Unsaturated alkyl groups can also be used, but they are less preferred because of their tendency to oxidize. Dehydroretinol (Vitamin A₂) and vitamin A aldehyde or retinene are also included in the term "vitamin A".



C:\WINWORD\1\ONAM\HMLH\SPEC\SP28244.DOC

THE PROCESS

Vitamin A is placed in a vessel which is shielded from light sources. A metal vessel or glass vessel which has been painted black or coated with a black or non-light transmitting coating is acceptable.

Vitamin A is degassed by any conventional method. It is important to remove any dissolved oxygen from the vitamin A since oxygen can cause further oxidation or degradation of vitamin A in the initial heating steps used to purify the material. Preferably vitamin A is subjected to a vacuum of less than 5mm of mercury to degas the sample. Usually the sample is degassed at less than 0.5mm Hg.

An inert gas sparge is then introduced into the sample. Preferably nitrogen is used as the sparging agent. However, non-oxidizing gases such as carbon dioxide, helium, argon or neon can also be used.

The sample is then heated to a temperature below 170°C, preferably in the range of from about 95°C to about 150°C, and most preferably from about 130°C to about 150°C. The rate of heating is not critical. Generally the vitamin A is heated from room temperature to 150°C in 2-3 minutes.

The sample is heated and sparged with inert gas under reduced pressure, less than 5mm of mercury, preferably less than 1, and most preferably in the range of 0.3mm to 0.6mm of mercury. The preferred heating conditions are from about 130°C to about 150°C, with a pressure in the range of about 0.5mm of mercury. The sparging gas is provided to the vessel at a flow rate of 0.5 to 14 cc/min/g vitamin A. Under these temperature and pressure conditions most of the oxidation products and hydrocarbons volatilize and are removed with the nitrogen or inert gas sparging.

Since beta ionone is one of the key impurities and since its boiling point is 126°C at 12mm of mercury, it is used to measure the progress of the purification of the vitamin A. Many of the impurities boil or vaporize with or before beta ionone under these conditions. Thus, the absence of beta ionone can be used as an indicator that many of the hydrocarbons and lower molecular weight oxidation products have been removed. The presence of beta ionone can be detected using a gas chromatograph to analyze the volatiles obtained by heating the sample to 50°C. Other analysis techniques can also be used.

Conventional oil deodorization or stripping equipment can be used. Then film evaporators, molecular still and deodorization units (batch or continuous) are acceptable.

It generally takes up to 120 minutes to remove the impurities. The exact time depends on sample size and the vessel configuration and the efficiency of the system. For a rotary evaporator from 15 minutes to 120 minutes is required. For a wiped

film evaporator the removal of impurities is accomplished in less than 10 minutes and usually on the order of 30 seconds to 5 minutes.

- 5 The purified vitamin A is mixed with tocopherol, and degassed again if necessary. Any tocopherol isomer can be used. The most preferred isomer is the alpha isomer which is also vitamin E. Tocopherol acts as an anti-oxidant and also reduces the amount of oxygen contacting the vitamin A. Tocopherol oxidizes less readily than vitamin A, and thus, is effective in stabilizing purified vitamin A.
- 10 Generally from 0.5:1 to 2:1 parts of tocopherol to vitamin A are used. The tocopherol can be added to the vitamin A prior to the purification step also. Preferably the ratio of tocopherol to vitamin A is 0.75:1 to 1:1.

- 15 The invention thus provides a vitamin A as herein described, which contains less than 3% beta-ionone and less than 2% cis-isomer of vitamin based on the weight of vitamin A.

The invention still further provides a process as herein described, wherein the vitamin A is an alkyl ester of retinol, and the tocopherol is alpha tocopherol and wherein the vitamin A contains less than 3% beta-ionone and less than 2% cis-isomers of vitamin A based on the weight of vitamin A.



The vitamin A prepared by the process herein is characterized by the following composition:

<u>COMPONENT</u>	<u>PERCENT BY WEIGHT</u>
vitamin A, trans isomer	33 to 66
tocopherol	33 to 66
beta-ionone	0 to 0.33
cis-isomers of vitamin A	0 to 0.33

It is substantially free of beta-ionone and solvents. By "substantially free" is meant that the levels of these materials in the vitamin A are less than 5% by weight of the vitamin A content. The level of β -ionone and other hydrocarbon impurities are measured by a gas chromatographic method. These materials are volatile at 50°C and their concentration in the headspace of the sample tube is proportional to their concentration in the vitamin A. Measuring the total decrease in β -ionone content in the volatiles confirms the low levels of impurities remaining in the vitamin A.

The vitamin A and tocopherol mixture can be in the form of a liquid oil, spray dried or encapsulated with gums, starches, pectin, gelatin, lipid hardstocks, ethyl cellulose or other suitable materials. Preferably, dextrin and gum acacia are used for the encapsulation. Any conventional encapsulation technique can be used to prepare such products. The vitamin A and tocopherol can also be admixed with other food ingredients.

The solidification or encapsulation of the vitamin A helps protect the vitamin A from interaction with ultraviolet light. The suppression of ultraviolet light absorption increases the stability of the purified vitamin A. The level of tocopherol mixed with the vitamin A when it is solidified in a carrier either as a beadlet or a powder or encapsulated is less than required in the liquid form. From about 0.05:1 to about 2:1 of tocopherol to vitamin A is used. Preferably from about 0.1:1 to about 1:1 is used.



The product prepared by this process is stable for up to three months against oxidation, and is essentially tasteless and odorless. To prolong the stability of purified vitamin A it should be stored in an oxygen free atmosphere and protected from light. Opaque packaging or an amber bottle can be used to protect it during storage. Liquid product is tested for stability under ambient temperature conditions in the presence of air and exposure to about 8 hours of day of fluorescent light.

Other antioxidants such as BHA, BHT and ascorbyl palmitate can be added to the compositions. In a preferred embodiment materials that suppress oxygen permeability into the vitamin A/tocopherol mixture are added. For example, stearyl alcohol can be used for this purpose. The stearyl alcohol forms a crystal lattice which will protect the vitamin A by providing a protective layer.

EXAMPLE I

A 500 ml cylindrical vessel which has been shielded from light and equipped to work with a rotary evaporator is charged with a 41.2 gm sample of unstabilized high potency vitamin A palmitate. The vessel is equipped with a dip tube which can be used to sparge the vessel with nitrogen. The volatiles are collected onto a cold finger condenser. The sample is first placed under vacuum at 0.1mm of mercury to degas the sample. The nitrogen sparge is then introduced at a flow rate of ~8cc/min./g sample. The sample is quickly heated to a temperature of 150°C by immersing the vessel in an oil bath maintained at 150°C. The introduction of the nitrogen sparge causes the vacuum to rise to 0.5mm of mercury. The product is heated for 120 minutes under these conditions.

The vitamin A is then cooled to room temperature, the vessel opened, and alpha-tocopherol mixed with it. The mixture is then degassed under 0.1-0.5mm Hg. then saturated with nitrogen. The ratio of alpha tocopherol to vitamin A palmitate is 1:1 by weight.

This material is then mixed with potato starch to a concentration of 5% vitamin A palmitate and sprinkled on to a potato chip. When 32 panelists were asked to evaluate the product for off flavor, acceptability, saltiness and potato flavor, 80% of the panelists saw no difference between the control sample without vitamin A addition and the product containing the vitamin A and E mixture; 17% of the panelists found less off flavor in the vitamin A and E product. The product contained 210 ppm of vitamin A and 210 ppm of tocopherol.

A high quality commercial vitamin A powder which had not been purified by the process described herein was tested at 150 ppm level on potato chips. In this panel only 48% of the panelists saw no difference and 36% of the panelists indicated that the vitamin A sample had more off flavor.

EXAMPLE II

Four different conditions were used to purify a commercial vitamin A sample having 1.8 million IUs (International Units). The general treatment was as in Example I. Before the sample was purified the volatiles at 50°C were analyzed by gas chromatography using the method described below. This sample is designated as the Control.

The purified vitamin A was analyzed by the same method. The results are provided in the following table. As is evident, the total amount of volatiles decreased by about 60% with all of the treatments. Importantly, the amount of β -ionone was decreased significantly in the samples.

Volatile Measurements on Vitamin A Liquids

	<u>Control</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>
Temperature	-	95°C	150°C	170°C	150°C
Pressure (mmHg)	-	2-3 mmHg	3-4 mmHg	3-4 mmHg	0.5 mmHg
Time (min.)	-	120	120	120	120
Sample wt. grams	0.102	0.126	0.145	0.130	0.136
Total Peak Area	786508	160217	120578	256278	801
<u>β-ionone Count</u>	16373	3201	2202	4959	59
g. sample x 100					

EXAMPLE III

A liquid vitamin A is purified by the method of Example I. Two different samples are encapsulated in gelatin to form a powdered vitamin A sample. One sample contains 5% tocopherol, the other 50% tocopherol. The solid encapsulated product is sprinkled on potato chips and is tested for stability at one week at 100°F (38°C) in air. The products are stable and show very little difference in taste compared to a control product that is stored under the same conditions. No deterioration of Vitamin A content is observed. The products are then stored for a second week at 100°F (38°C) in air and under constant exposure to fluorescent light. Some loss of vitamin A occurs, but the 5% sample still tastes equal or better than the control product under the same conditions. These are extremely stringent storage conditions and under normal usage, food containing the solid or encapsulated vitamin A/tocopherol of this inventions is expected to be storage stable in commercial practice.

Analytical ProcedureGas Chromatographic Monitoring of Volatile ComponentsSampling System

The sampling system consists of a Tekmar LSC 2000 Purge and Trap unit fitted with a 5 ml needle sparge tube. The sparge tubes are impeccably cleaned and baked at 140°C prior to use. The Purge and Trap unit is prepared for use by cycling it through multiple blank runs while baking the trap at a temperature of 225°C for 8 minutes. This continues until the trap is essentially clean of any background contaminants.

Approximately 0.150 grams of test material is weighed directly into a cool sparge tube and immediately placed on the Tekmar unit. The sample is heated to 50°C and purged with nitrogen at volumetric flow rate of 6-20 cc/minute for 4 minutes. Volatiles are collected onto a trap containing Tenax GC adsorbent. When complete, the trap is preheated to 100°C for 2 minute. The trap is then back flushed at a desorb temperature of 180°C for 4 minutes. Transfer lines and switching valve are maintained at 200°C. The sample mounting block is maintained at 100°C.

The desorbed volatiles are flushed into a Hewlett Packard 5890 gas chromatograph equipped with a Hewlett Packard 3396 electronic integrator. The detector is a flame ionization type. The fused silica capillary column is 50 meters long by 0.25 mm internal diameter. The capillary column is a DB-1 type.

The gas chromatograph uses a split injection flow. Initial oven temperature is 40°C. The chromatograph is programmed to automatically change the temperature of the oven at the rate of 10°C/minute to a final oven temperature of 350°C. Initial oven hold time is 5 minutes. The injector temperature is 200°C and the detector temperature is 350°C. The split ratio is set at 10 to 50ml/minute.

The integrator is set at manufacturer's recommendations so the peak integrations are optimized.

The recorder is a linear recorder which did not change the attenuation according to peak height.

Food Uses

The shelf stable purified vitamin A can be used in any food product. It can be added to oils, breads, baked goods, confections, snacks, beverages and other oil containing foods. It can also be used in cosmetics and in vitamin supplements. It is particularly useful in liquid supplements where taste and odor are a problem.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A shelf stable, purified vitamin A preparation wherein said preparation is substantially free of beta-ionone and solvents, and wherein less than 5% of the vitamin A is a cis-isomer, comprising a mixture of tocopherol and vitamin A, the ratio of tocopherol to vitamin A being from 0.5:1 to 2:1.
2. A shelf stable, purified vitamin A preparation which is substantially free of beta-ionone and solvents, and wherein less than 5% of the vitamin A is a cis-isomer, comprising a mixture of tocopherol and vitamin A, the ratio of tocopherol to vitamin A being from 0.05:1 to 2:1; said vitamin A being encapsulated.
3. A vitamin A according to claim 1 or 2 wherein the vitamin A is an alkyl ester of retinol, and wherein the tocopherol is alpha tocopherol.
4. A vitamin A according to any one of claims 1 to 3 wherein the vitamin A is retinol acetate or retinol palmitate, and wherein the tocopherol is alpha tocopherol.
5. A vitamin A according to any one of claims 1 to 4 which contains less than 3% beta-ionone and less than 2% cis-isomers of vitamin A based on the weight of vitamin A.
6. A vitamin A according to any one of claims 2 to 5 wherein the vitamin A is encapsulated with a member of the group selected from gums, starches, pectin, gelatin, lipid, hardstocks, ethyl cellulose or mixtures thereof.
7. A process for removing off-flavour and odors from vitamin A comprising:
 - (a) degassing a sample of vitamin A;
 - (b) heating degassed vitamin A in the absence of light at a pressure of less than 4 mm Hg and a temperature of less than 170°C with an inert gas sparge until substantially all of the beta-ionone and solvents are removed;
 - (c) mixing the vitamin A with from 0.5 to 2 part of tocopherol/part of vitamin A.



8. A process for removing off-flavor and odors from vitamin A comprising:

(a) degassing a sample of vitamin A;

5 (b) heating degassed vitamin A in the absence of light at a pressure of less than 4 mm Hg and a temperature of less than 170°C with an inert gas sparge until substantially all of the beta-ionone and solvents are removed;

(c) mixing the vitamin A with from 0.05:1 to 2:1 parts of tocopherol/part of vitamin A: and

10 (d) encapsulating the vitamin A tocopherol mixture with a member of the group selected from gums, starches, pectin, gelatin, lipid hardstocks, ethyl cellulose or mixtures thereof.

9. A process according to claim 7 or claim 8 wherein the vitamin A is mixed with the tocopherol before the heating step and wherein the vitamin A is heated at
15 a temperature of from 130°C to 150°C at a pressure of 0.3 to 0.6 mm Hg and wherein the sparging gas is nitrogen.

10. A process according to any one of claims 7 to 9 wherein the vitamin A is an alkyl ester of retinol, and the tocopherol is alpha tocopherol and wherein the vitamin A contains less than 3% beta-ionone and less than 2% cis-isomers of
20 vitamin A based on the weight of vitamin A.

11. A food product comprising the composition of any one of claims 1 to 4.

12. A shelf stable purified vitamin A preparation according to claim 1 or claim 2, substantially as hereinbefore described with reference to any one of the Examples.

25 13. A process for removing off-flavor and odors from vitamin A, according to claim 7 or claim 8 and substantially as hereinbefore described with reference to any one of the Examples.

DATED: 26 February, 1999

30 PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

THE PROCTER & GAMBLE COMPANY



IC: C:\WINWORD\ILON\AMLMH\MLH5SPEC\ISP28244.DOC